Company / Return on Equity (ROE)
RIGEL PHARMACEUTICALS INC Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
93.8%
FY2025
5-year range
-59.0% / 531.8%
FY2021-FY2025
Trend
-82.4%
vs FY2024
Sector context
#2 of 190
Health Care
What the data says
Among 190 Health Care companies, RIGEL PHARMACEUTICALS INC is in the top 1% for return on equity (roe). Return on Equity (ROE) has fluctuated over the past 8 years, ranging from -125.8% in FY2018 to 531.8% in FY2024.
Based on SEC 10-K filings.
93.8% in FY2025 with a 5-year CAGR of +181.2%. Ranks 2nd among 190 companies in Health Care.
Improved from -59.0% to 93.8% over the past 4 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- +181.2pp
- 10-Year Change
- -
Sector benchmark
+285.9% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 82.4% year-over-year.
- Currently 144.2pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 93.8% | -82.4% |
| FY2024 | 531.8% | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -59.0% | +32.5% |
| FY2020 | -87.4% | +29.7% |
| FY2019 | -124.3% | +1.2% |
| FY2018 | -125.8% | -62.3% |
| FY2017 | -77.5% | +38.4% |
| FY2016 | -125.8% | -123.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026